StockUS listing USXRTXNASDAQHealthcareValue Trap

XORTX Therapeutics Inc(XRTX) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk51Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 2.00M
Reward Ratingⓘ40 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ51 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on XRTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is XORTX Therapeutics Inc?

, a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada.

AI Brief Pro

The brief on XORTX Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is XORTX Therapeutics Inc?

, a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.00M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.813
Insider Activity
12M windowNo data
No insider activity data available for this ticker.